Skip Navigation


JAC Advance Access originally published online on July 1, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/2/152    most recent
dkg306v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Swanson-Mungerson, M.
Right arrow Articles by Portis, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swanson-Mungerson, M.
Right arrow Articles by Portis, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 152-154
© 2003 The British Society for Antimicrobial Chemotherapy

Leading Article

Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein–Barr virus (EBV)-associated diseases

Michelle Swanson-Mungerson, Masato Ikeda, Lori Lev, Richard Longnecker* and Toni Portis

Department of Microbiology and Immunology, Northwestern University Medical School, Chicago, IL 60611, USA

Keywords: antivirals, Epstein–Barr virus, tyrosine kinases, microarray analysis

The first 150 words of the full text of this article appear below.


   Introduction
 
Epstein–Barr Virus (EBV) is a human herpesvirus that establishes a lifelong latent infection in B lymphocytes. EBV is associated with the development of several malignancies of lymphoid origin, including Burkitt’s lymphoma, Hodgkin’s disease, and lymphoproliferative disorders arising in immunocompromised patients.1 There are also diseases of epithelial origin associated with EBV infection, including nasopharyngeal carcinoma and oral hairy leucoplakia.1

In vitro, EBV can transform infected lymphocytes into continuously proliferating lymphoblasts. In fact, most functional studies of EBV proteins have been carried out using lymphoblastoid cell lines (LCLs) established in vitro.2,3 Expression of viral latency-associated transcripts in vivo appears to be tightly regulated. Whereas viral Epstein–Barr nuclear antigen 1 (EBNA1), EBV-encoded RNAs (EBERs), latent membrane protein 1 (LMP1) and LMP2A transcripts have been detected in tumour cells from patients with EBV-associated malignancies, LMP2A is one of the most consistently identified in vivo in B cells from healthy individuals harbouring a . . . [Full Text of this Article]


   LMP2A and B cell receptor (BCR) signalling
 

   DNA microarray analysis of LMP2A-expressing cells
 

   Functional inhibitors to study LMP2A signalling
 

   Summary and concluding statement
 

   Acknowledgements
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ASH Education BookHome page
R. M. Meyer, R. F. Ambinder, and S. Stroobants
Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice
Hematology, January 1, 2004; 2004(1): 184 - 202.
[Abstract] [Full Text] [PDF]